Alnylam/Roche Report KARDIA-2 Topline Study Results, The Study Met The Primary Endpoint Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
Author: Benzinga Newsdesk | March 05, 2024 08:40am